Oruka Therapeutics (ORKA) Net Income towards Common Stockholders (2010 - 2024)
Oruka Therapeutics (ORKA) posted quarterly Net Income towards Common Stockholders of -$18.1 million for Q2 2024, down 1085.44% year-over-year from $1.8 million in Q3 2023, and down 157.93% quarter-over-quarter from -$7.0 million in Q1 2024.
Powered by 
Analysis
Oruka Therapeutics (ORKA) Net Income towards Common Stockholders (2010 - 2024) Analysis & Trends
Oruka Therapeutics' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$18.1 million for Q2 2024.
- In Q2 2024, Net Income towards Common Stockholders fell 1085.44% year-over-year to -$18.1 million; the TTM figure through Mar 2025 stood at -$18.1 million (down 58.4% YoY), while the FY2023 annual figure was -$60.9 million, up 5.32% from the prior year.
- Net Income towards Common Stockholders for Q2 2024 stood at -$18.1 million, down from -$7.0 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$1.1 million in Q4 2023, with the low at -$18.1 million in Q2 2024.
- The 5-year median for Net Income towards Common Stockholders is -$2.8 million (2022), against an average of -$3.9 million.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders soared 79.32% in 2022, then tumbled 1085.44% in 2024.
- Oruka Therapeutics' Net Income towards Common Stockholders stood at -$5.2 million in 2020, then retreated by 8.24% to -$5.7 million in 2021, then jumped by 79.32% to -$1.2 million in 2022, then increased by 5.03% to -$1.1 million in 2023, then slumped by 1521.35% to -$18.1 million in 2024.
- Business Quant data shows ORKA's Net Income towards Common Stockholders at -$18.1 million in Q2 2024, -$7.0 million in Q1 2024, and -$1.1 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Oruka Therapeutics | 5.83 Bn | 4.10 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -2.68 Mn |
| Mar 31, 2024 | -2.01 Mn |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | -1.17 Mn |
| Sep 30, 2022 | -2.33 Mn |
| Jun 30, 2022 | -3.15 Mn |
| Mar 31, 2022 | -3.27 Mn |
| Dec 31, 2021 | -5.68 Mn |
| Sep 30, 2021 | -4.71 Mn |
| Jun 30, 2021 | -4.83 Mn |
| Mar 31, 2021 | -4.10 Mn |
| Dec 31, 2020 | -3.09 Mn |
| Sep 30, 2020 | -1.99 Mn |
| Jun 30, 2020 | -1.30 Mn |
| Mar 31, 2020 | -1.32 Mn |
| Dec 31, 2019 | -242,000.00 |
| Sep 30, 2019 | -1.16 Mn |